Neuroprotection Therapeutics Market

Neuroprotection Therapeutics Market Outlook (2022-2027)

The global neuroprotection therapeutics market is anticipated to expand rapidly at a CAGR of 6.8% over the 2022-2027 forecast period. The market is expected to secure a market value of around US$ 85.1 billion by 2027, up from US$ 61.25 billion in 2022.

Neuroprotection therapeutics shield the brain's neurons against damage and deterioration. These drugs are used to treat a variety of disorders of the central nervous system, including traumatic brain injuries, Parkinson's disease, and Alzheimer's disease.

Age considerably raises the prevalence of neurological diseases. Thus, when average life expectancy rises, there will be greater demand for neuroprotective therapies, creating a sizable market for new medications to treat these illnesses.

Report Attributes	Details
Neuroprotection Therapeutics Market Size (2022)	US$ 61.25 Billion
Projected Market Value (2027)	US$ 85.1 Billion
Global Market Growth Rate (2022-2027)	6.8% CAGR
Key Companies Profiled	Allergan PLC Daiichi Sankyo Co., Ltd. Astrocyte Pharmaceuticals Inc. AstraZeneca PLC Biogen, Inc. Novartis International AG Eli Lilly and Company F. Hoffmann-La Roche AG Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd.

Demand Analysis of Neuroprotection Therapeutics (2017-2021) Vs. Market Outlook (2022-2027)

“Increasing Stroke & Traumatic Central Nervous System Injuries Driving Demand for Neuroprotection Therapeutics”

According to Fact.MR- a market research and competitive intelligence provider- worldwide demand for neuroprotection therapeutics and drugs is expected to increase at a CAGR of 6.8% from 2022 to 2027.

The need for the treatment of brain injuries primarily brought on by auto accidents and the rising incidence of neurodegenerative illnesses, particularly in older populations are factors driving the demand for neuroprotective therapies.

The potential for the introduction of innovative medications is significantly increased by the high incidence of neurogenerative disease and the dearth of particular therapeutic alternatives.

Some of the key drivers anticipated to propel market expansion during the forecast period include increasing stroke and traumatic central nervous system injuries. One of the key drivers propelling market expansion is the increased demand for the product for a variety of uses in hospitals, medical facilities, and nursing homes.

Therapeutics for neuroprotection may lessen the effects of stroke. Small-molecule medicines, therapeutic monoclonal antibodies, gene and cell treatments, and other substances are among the medications for neuroprotection that are now under clinical development. A process called neuroprotection, or the prevention of neuronal loss, is mediated by numerous biological mechanisms.

Trauma, shock, stroke, sepsis, traumatic brain injury (TBI), and burst brain aneurysms are the most prevalent disorders linked to nervous system involvement, and their rising incidence is the main factor driving the neuro critical care market expansion.

Why is Demand for Neuroprotection Therapeutics Rising Rapidly?

“Implementation of Medical Professional Training Programs in Healthcare Facilities to Surge Adoption of Neuroprotection Therapeutics”

The market for neuroprotection therapeutics may see many potential opportunities due to technological developments in the healthcare industry and the rising demand for innovative neuroprotective products in light of considerable research on drugs for the effective preservation of brain cells.

Therapeutics for neuroprotection offer drugs that shield the brain and central nervous system. These products work well to regenerate cells that may have been damaged by trauma or stress. These features and advantages could significantly boost the market for neuroprotection therapeutics.

The market for neuroprotection treatments is expected to rise due to the steadily growing senior population and the increased occurrence of disorders affecting the central nervous system.

The market for neuroprotection medicines will have a lot of room to develop as a result of the healthcare industry's growing demand for these drugs. The prevalence of life-threatening illnesses and brain injuries is projected to rise, creating new opportunities for the market for neuroprotection therapeutics to expand.

The development of diagnostic and therapeutic approaches, which has produced remarkable outcomes, has been greatly aided by the next-generation products. These advancements could portend the market for neuroprotection therapeutics expanding over the coming years.

The implementation of medical professional training programs in healthcare facilities to ensure that patients receive the best care possible could act as a growth factor for the neuroprotective agents market.

With government financing and initiatives, the emphasis on creating a complete and well-equipped hospital infrastructure has grown significantly over time. Government organizations are adopting a variety of actions to upgrade healthcare infrastructure and offer kind reimbursement practices.

What is Impeding Neuroprotection Therapeutics Market Revenue Growth?

“Strict Regulatory Approvals & High Costs Associated with Related R&D”

The lack of clinical research, high costs associated with R&D, strict regulatory approvals, and the high failure rate of a majority of potential medications in clinical trials restrain market expansion to some extent.

Why is North America Expected to Lead the Neuroprotection Therapeutics Market?

“High Popularity of Preventative Healthcare Practices in North America”

North America is anticipated to occupy a significant market share in the neuroprotection therapeutics market during the projection period. The Parkinson's Foundation estimates that 60,000 Americans receive a Parkinson's diagnosis each year. Consequently, North America is the main market for neuroprotection therapeutics.

Nearly 5 to 7 million people worldwide are thought to have Parkinson's disease, which would raise the need for neuroprotective medications and encourage research and development. This is addressed by the rising popularity of preventative healthcare practices in North America.

Country-wise Insights

What are the Growth Prospects for the U.S. Neuroprotection Therapeutics Market?

“Increasing Government Support & Funding for Research Initiatives in the U.S.”

The U.S. neuroprotection therapeutics market is projected to expand at the highest CAGR from 2022 to 2027. The number of geriatricians in the United States will need to nearly triple by 2050 to appropriately care for the anticipated number of people with Alzheimer's disease, according to the Alzheimer's Association. As a result, an expanding patient base is anticipated to aid in the market expansion over the coming years.

Due to the growing impact of the disease, government support and funding for research initiatives are rising. The U.S. Congress contributed roughly US$ 10 million to multiple sclerosis research and may provide an additional US$ 20 million. The U.S. market is expanding as a result of expanding healthcare infrastructure, supportive government programs, and increased illness burden.

Why is China a Prominent Neuroprotection Therapeutics Market?

“Rapid Expansion of Biopharmaceutical Industry in China”

The neuroprotection therapeutics market in China is anticipated to rise at a CAGR of 6.5% from 2022 to 2027. The demand for neuroprotective drugs in the region is anticipated to rise due to the established biopharmaceutical industry, large population, growing research activities, and growing demand for highly effective medications for rare neurological disease treatment.

Market expansion in China is being driven by the use of neuroprotective products along with recent technological advancements, higher spending on healthcare modernization programs, and the rise of medical tourism.

Category-wise Insights

Which Neuroprotection Therapeutic Product is Expected to Be Hugely Popular Over the Coming Years?

“Improved Effectiveness of Free Radical Trapping Agents in Halting Deterioration of Neural Cells”

Based on product, the neuroprotection therapeutics market is segmented into glutamate antagonists (anti-excitotoxic agents), free radical trapping agents (antioxidants), anti-inflammatory agents, neurotrophic factors (NTFs), and apoptosis inhibitors.

Free radical trapping agents (antioxidants) account for 38% share of the global neuroprotection therapeutics market. The significant rise is a result of the increased use of free radical trapping agents in the treatment of neurological diseases such as Alzheimer's and the improved effectiveness of antioxidants in halting the further deterioration of neural cells.

The rising need for effective medications, rising use of herbal extracts that trap free radicals, and increasing R&D efforts are the factors driving the demand for free radical trapping agents (antioxidants).

Which Medical Condition Accounts for Highest Need for Neuroprotection Therapeutics?

“Rise in R&D Efforts for Creation of Novel Drugs in Alzheimer's Disease Treatment”

Demand for neuroprotection therapeutics in Alzheimer's disease treatment remains dominant over other medical conditions such as dementia, epilepsy, and multiple sclerosis.

Alzheimer's symptoms include anxiety, loss of memory, lack of inhibitions, and problems with logic and understanding. It is frequently diagnosed through physical examinations, laboratory tests, brain imaging, mental status exams, and neuropsychological evaluation. As the world's population ages, the incidence of Alzheimer's disease rises, creating prospects for market expansion in the Alzheimer's treatment sector.

According to the World Population Prospects (WPP) report from the UN, there will be 1.4 billion Alzheimer's disease patients worldwide by 2030, growing at a pace of 3% each year. However, treatments for Alzheimer's are being developed and are expected to go on sale soon, spurring market expansion.

A rise in the demand for therapeutic targets, a rise in research & development efforts for the creation of novel drugs and therapies, an increase in the prevalence of Alzheimer's disease in the population, and an increase in spending on the healthcare infrastructure are all factors that have contributed to the growth of the Alzheimer's disease treatment industry.

Cotinine has been developed as a neuroprotective agent, and it enhances the performance of tasks involving the processing of information, concentration, and memory that are relevant to Alzheimer's disease.

Competitive Landscape

Companies in the neuroprotective therapeutics market are putting increased emphasis on spending money on product innovation and launches, along with enhancements to usefulness and result accuracy.

For instance :

• In 2021, Merck KGaA invested in Synthekine, a cytokine bioresearch firm, to increase the company's capabilities in the management of autoimmune illnesses.

Key Segments in Neuroprotection Therapeutics Industry Research

• By Product :

  • Free Radical Trapping Agents (Antioxidants)
  • Glutamate Antagonists (Anti-Excitotoxic Agents)
  • Apoptosis Inhibitors
  • Anti-inflammatory Agents
  • Neurotrophic Factors (NTFs)
  • Other Products

• By Medical Condition :

  • Alzheimer's Disease
  • Dementia
  • Epilepsy
  • Multiple Sclerosis

• By Application :

  • Prevention
  • Treatment

• By End User :

  • Hospitals
  • Clinics
  • Others

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa